Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.090 Biomarker disease BEFREE These results establish a strong rationale for developing kinase-directed inhibitors of IRE1α for MM therapy. 31371506 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.090 Biomarker disease BEFREE Here we show that in hematopoietic cells, including multiple myeloma (MM), lymphoma, and leukemia cell lines, ER stress leads to caspase-mediated cleavage of the key UPR sensor IRE1 within its cytoplasmic linker region, generating a stable IRE1 fragment comprising the ER-lumenal domain and transmembrane segment (LDTM). 31453810 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.090 AlteredExpression disease BEFREE Targeting SK2 synergistically contributed to ER stress and UPR activation induced by bortezomib, as evidenced by activation of the IRE1 pathway and stress kinases JNK and p38MAPK, thereby resulting in potent synergistic myeloma apoptosis in vitro. 28467788 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.090 Biomarker disease BEFREE The endoplasmic reticulum kinase inositol-requiring enzyme 1 (IRE1) and its downstream target X-box-binding protein 1 (XBP1) drive B-cell differentiation toward plasma cells and have been shown to contribute to multiple myeloma development; yet, little is known of the role of this pathway in diffuse large B-cell lymphoma (DLBCL). 28167662 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.090 Biomarker disease BEFREE Our study not only confirmed the utilization of topological data analysis in drug discovery but also identified a class of compounds with a unique mechanism of action as potent IRE1α-XBP1 inhibitors in the treatment of multiple myeloma. 27307600 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.090 GeneticVariation disease BEFREE Evidence implicating dysregulation of the IRE1/XBP-1s arm of the unfolded protein response (UPR) in cancer pathogenesis (e.g., multiple myeloma) has prompted the development of IRE1 RNase inhibitors. 24362465 2014
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.090 Biomarker disease BEFREE Taken together, our results demonstrate that blockade of XBP1 splicing by inhibition of IRE1α endoribonuclease domain is a potential therapeutic option in MM. 22538852 2012
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.090 Biomarker disease BEFREE To determine whether the Unfolded Protein Response (UPR) sensors (PERK, ATF6 and IRE-1) can be targeted to promote death of Multiple Myeloma (MM) cells. 22028791 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.090 AlteredExpression disease BEFREE Identification of compounds that target the activity of IRE1 alpha/XBP-1 may yield novel therapies for the treatment of multiple myeloma and other malignancies that rely on an intact UPR. 12902539 2003